Literature DB >> 30217318

Neutrophil/lymphocyte ratio is associated with survival in synovial sarcoma.

Dorian Yarih García-Ortega1, Alethia Álvarez-Cano2, Luis Adolfo Sánchez-Llamas2, Claudia H S Caro-Sanchez3, Héctor Martínez-Said2, Kuauhyama Luna-Ortiz2, Mario Cuéllar-Hübbe2.   

Abstract

BACKGROUND: Synovial sarcoma is a rare malignant soft tissue tumor, more common in adolescents and young adults and entails a poor prognosis. Several good prognostic factors have been well established such as age less than 25, size less than 5 cm and absence of a poorly differentiated component. Inflammation has a well-established role in tumor proliferation and survival. The aim of this study was to investigate the prognostic significance of the neutrophil/lymphocyte ratio (NLR) in a large cohort of synovial sarcoma patients.
METHODS: Retrospective study of 169 consecutive patients. We analyzed the relation of preoperative NLR on disease-free survival (DFS) and overall survival (OS) using Kaplan-Meier curves and Cox proportional models.
RESULTS: Of the 169 patients included, there were 90(53.3%) females and 79(46.7%) males. Median age was 32yo (11-73). Median survival was 34.1 and mean disease-free survival was 21.4 months. Mean tumor size was 12.5 cm (1.2-77 cm). Applying receiver operating curve analysis, we determined a cut-off value of 3.5. In univariate and multivariate analysis, increased NLR was significantly associated with poor OS. A <3.5 NLR was an independent prognostic factor in all stages (p = 0.002).
CONCLUSIONS: NLR >3.5 was found to be a reliable prognostic factor in this cohort. Given its widespread availability, we believe it's use in clinical practice and further clinical trials should be considered.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Inflammation; Neutrophil/lymphocyte ratio; Prognostic factor; Synovial sarcoma

Mesh:

Year:  2018        PMID: 30217318     DOI: 10.1016/j.suronc.2018.07.012

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  6 in total

1.  Clinical comparison of tenosynovial giant cell tumors, synovial chondromatosis, and synovial sarcoma: analysis and report of 53 cases.

Authors:  Wei Wang; Man-Mei Long; Cheng-Jiang Wei; Xi-Wei Cui; Jie-Yi Ren; Yi-Hui Gu; Qing-Feng Li; Shun-Dong Dai; Bin Gu; Zhi-Chao Wang
Journal:  Ann Transl Med       Date:  2021-07

2.  Pretreatment Inflammatory Indexes as Prognostic Predictors of Survival in Patients Suffering From Synovial Sarcoma.

Authors:  Yuan Cheng; Fei Mo; Lutong Pu; Qingfang Li; Xuelei Ma
Journal:  Front Oncol       Date:  2019-09-24       Impact factor: 6.244

3.  Impact of adaptive intensity-modulated radiotherapy on the neutrophil-to-lymphocyte ratio in patients with nasopharyngeal carcinoma.

Authors:  Ning Han; Xintong Lyu; Guang Li; Qiao Qiao
Journal:  Radiat Oncol       Date:  2019-08-22       Impact factor: 3.481

4.  Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy.

Authors:  D Viñal; L Gutierrez-Sainz; D Martinez; J A Garcia-Cuesta; J Pedregosa; J Villamayor; L Ostios; D Sanchez-Cabrero; O Higuera; A Pinto; N Rodriguez-Salas; E Espinosa; J de Castro; J Feliu
Journal:  Clin Transl Oncol       Date:  2020-11-23       Impact factor: 3.405

5.  Epidemiological profile of soft tissue sarcomas of the extremities: Incidence, histological subtypes, and primary sites.

Authors:  Dorian Yarih García-Ortega; Miguel Angel Clara-Altamirano; Karla Susana Martín-Tellez; Claudia Haydee Sarai Caro-Sánchez; Alethia Álvarez-Cano; Leonardo S Lino-Silva; Rosa A Salcedo-Hernández; Cuauhtémoc de la Cruz Ruvalcaba-González; Hector Martínez-Said; Kuauhyama Luna-Ortiz; Sylvia Veronica Villavicencio-Valencia; Mario Cuellar-Hubbe
Journal:  J Orthop       Date:  2021-04-02

6.  Meta-Analysis of Hematological Biomarkers as Reliable Indicators of Soft Tissue Sarcoma Prognosis.

Authors:  Long-Qing Li; Zhen-Hua Bai; Liang-Hao Zhang; Yan Zhang; Xin-Chang Lu; Yi Zhang; Yong-Kui Liu; Jia Wen; Jia-Zhen Li
Journal:  Front Oncol       Date:  2020-01-30       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.